<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916732</url>
  </required_header>
  <id_info>
    <org_study_id>C16-08</org_study_id>
    <secondary_id>2016-A00399-42</secondary_id>
    <nct_id>NCT02916732</nct_id>
  </id_info>
  <brief_title>Zika Virus Infection's Pregnancy Consequences in French Department of America</brief_title>
  <acronym>ZIKA-DFA-FE</acronym>
  <official_title>Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Zika (ZIKV) epidemic has spread into the three French Overseas Departments in the
      Caribbean (DFAs). It is therefore urgent to set up tools to collect clinical and paraclinical
      data for the evaluation of potential complications due to having ZIKV infection during
      pregnancy. This study is meant to collect, within usual care practices, clinical and
      paraclinical information which will allow the precise description of the consequences of ZIKV
      infection occurring during pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational, non-interventional study that has been integrated into
      the usual standard of care practices. All information and biological samples collected during
      the course of this project will be done through the new medical standard of care which has
      been put in place during the ZIKV epidemic in the DFAs; this new standard of care is a result
      of existing recommendations from medical professionals and/or public health authorities.
      Outside of these recommendations, no invasive procedure will be done simply to satisfy an
      objective of this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of ZIKV infection during pregnancy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of microcephaly and other fetal abnormalities</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of risk factor for the occurence of congenital abnormalities</measure>
    <time_frame>12 month</time_frame>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">26980</enrollment>
  <condition>Incidence of ZIKV Infection on Fetus During the Pregnancy</condition>
  <arm_group>
    <arm_group_label>Module 1</arm_group_label>
    <description>Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2</arm_group_label>
    <description>Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 3</arm_group_label>
    <description>Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 4</arm_group_label>
    <description>Biological collection of maternal blood and cord blood collected during the delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 5</arm_group_label>
    <description>Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  bio-bank of serum from all pregnant women.

        -  bio-bank of maternal blood and infant cord blood

        -  bio-bank of maternal blood and fetal tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population of this study is women who have been pregnant during the 2016 ZIKV Epidemic
        in the DFAs. Five study arms (hereafter called 'modules') have been defined with various
        inclusion criteria for each module.

        M1: Pregnant women with clinical signs of acute ZIKV infection

        Module 2: Pregnant women for which an abnormality has been detected in the fetus.

        Module 3: Bio-bank of serum, collected once per trimester, from all pregnant women.

        Module 4: Bio-bank of maternal blood and infant cord blood, taken the day of birth in all
        mothers and their babies in the 3 DFAs.

        Module 5: Bio-bank of maternal blood and fetal tissues from women in whom the pregnancy was
        terminated due to miscarriage, abortion on medical grounds, or a fetal death in-utero.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        M1:

        Inclusion Criteria:

          -  On-going pregnancy regardless the presumed date of birth

          -  Clinical signs suggestive of ZIKV infection

          -  Whatever the RT-PCR analysis

        Exclusion Criteria:

          -  Minor

          -  No consent

        M2:

        Inclusion Criteria:

          -  Head circumference &lt; 5th percentile

          -  Other brain morphological abnormality

          -  Hydramnios

          -  Intrauterine growth restriction (IUGR)

        Exclusion Criteria:

          -  Minor

          -  No consent

        M3:

        Inclusion Criteria:

          -  Pregnant woman during epidemic period of ZIKV

        Exclusion Criteria:

          -  Minor

          -  Opposition

        M4:

        Inclusion Criteria:

          -  Delivery during epidemic period of ZIKV

        Exclusion Criteria:

          -  Minor

          -  No consent

        M5:

        Inclusion Criteria:

          -  Spontaneous abortion or fetal death in utero during epidemic period of ZIKV

        Exclusion Criteria:

          -  Minor

          -  No consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno Hoen</last_name>
    <email>bruno.hoen@chu-guadeloupe.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Andrée Rosemon (CHAR)</name>
      <address>
        <city>Cayenne Cedex</city>
        <zip>97306</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort de France Cedex</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Pointe à Pitre/Les Abymes</name>
      <address>
        <city>Pointe A Pitre</city>
        <zip>97139</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH de l'Ouest Guyanais Franck Joly (CHOG)</name>
      <address>
        <city>Saint-laurent-du-maroni</city>
        <zip>97320</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asymptomatics</keyword>
  <keyword>microcephaly</keyword>
  <keyword>abnormalities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

